Impact of collagen-induced arthritis on the pharmacokinetic disposition of voriconazole, a widely used antifungal agent: in vitro and in vivo investigations in DBA/1J mice

References

• Barre J, Houin G, Brunner F, et al. (1983). Disease-induced modifications of drug pharmacokinetics. Int J Clin Pharmacol Res 3:215–26.
   PubMedGoogle Scholar
• Bishu S, Su EW, Wilkerson ER, et al. (2014). Rheumatoid arthritis patients exhibit impaired Candida albicans-specific Th17 responses. Arthritis Res Ther 16:R50.
   PubMed Web of Science ®Google Scholar
• Brand DD, Latham KA, Rosloniec EF. (2007). Collagen-induced arthritis. Nature Protocols 2:1269–75.
   PubMed Web of Science ®Google Scholar
• Coutant DE, Kulanthaivel P, Turner PK, et al. (2015). Understanding disease-drug interactions in cancer patients: implications for dosing within the therapeutic window. Clin Pharmacol Ther 98:76–86.
   PubMed Web of Science ®Google Scholar
• Dolton MJ, Ray JE, Chen SC, et al. (2012). Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring. Antimicrob Agents Chemother 56:4793–9.
   PubMed Web of Science ®Google Scholar
• Elewa H, El-Mekaty E, El-Bardissy A, et al. (2015). Therapeutic drug monitoring of voriconazole in the management of invasive fungal infections: a critical review. Clin Pharmacokinet 54:1223–35.
   PubMed Web of Science ®Google Scholar
• Galli M, Antinori S, Atzeni F, et al. (2017). Recommendations for the management of pulmonary fungal infections in patients with rheumatoid arthritis. Clin Exp Rheumatol 35:1018–28.
   PubMed Web of Science ®Google Scholar
• Giri P, Naidu S, Patel N, et al. (2016). Evaluation of in vitro cytochrome P450 inhibition and in vitro fate of structurally diverse N-oxide metabolites: case studies with clozapine, levofloxacin, roflumilast, voriconazole and zopiclone. Eur J Drug Metab Pharmacokinet 42: 677–688.
   Web of Science ®Google Scholar
• Hohmann N, Kocheise F, Carls A, et al. (2016). Dose-dependent bioavailability and CYP3A inhibition contribute to non-linear pharmacokinetics of voriconazole. Clin Pharmacokinet 55:1535–45.
   PubMed Web of Science ®Google Scholar
• Jeong S, Nguyen PD, Desta Z. (2009). Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A. Antimicrob Agents Chemother 53:541–51.
   PubMed Web of Science ®Google Scholar
• Job KM, Olson J, Stockmann C, et al. (2016). Pharmacodynamic studies of voriconazole: informing the clinical management of invasive fungal infections. Expert Rev anti Infect Ther 14:731–46.
   PubMed Web of Science ®Google Scholar
• Listing J, Gerhold K, Zink A. (2013). The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford) 52:53–61.
   PubMed Web of Science ®Google Scholar
• Ma L, He L, Wang L, et al. (2016). Altered expression of transporters, its potential mechanisms and influences in the liver of rodent models associated with diabetes mellitus and obesity. Eur J Drug Metab Pharmacokinet 41:199–210.
   PubMed Web of Science ®Google Scholar
• Mikulska M, Novelli A, Aversa F, et al. (2012). Voriconazole in clinical practice. J Chemother 24:311–27.
   PubMed Web of Science ®Google Scholar
• Murayama N, Imai N, Nakane T, et al. (2007). Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes. Biochem Pharmacol 73:2020–6.
   PubMed Web of Science ®Google Scholar
• Nelson AC, Huang W, Moody DE. (2001). Variables in human liver microsome preparation: impact on the kinetics of l-alpha-acetylmethadol (LAAM) n-demethylation and dextromethorphan O-demethylation. Drug Metab Dispos 29:319–25.
   PubMed Web of Science ®Google Scholar
• Patel H, Giri P, Srinivas NR. (2017). Review of pharmacokinetic data of different drug classes in Goto-Kakizaki rats, a non-obese model for Type 2 diabetes mellitus: case studies and perspectives. Eur J Drug Metab Pharmacokinet 42:173–82.
   PubMed Web of Science ®Google Scholar
• Patel H, Joharapurkar AA, Pandya VB, et al. (2018). Influence of acute and chronic kidney failure in rats on the disposition and pharmacokinetics of ZYAN1, a novel prolyl hydroxylase inhibitor, for the treatment of chronic kidney disease-induced anemia. Xenobiotica 48:37–44.
   PubMed Web of Science ®Google Scholar
• Quinney SK, Zhang X, Lucksiri A, et al. (2010). Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin. Drug Metab Dispos 38:241–8.
   PubMed Web of Science ®Google Scholar
• Roffey SJ, Cole S, Comby P, et al. (2003). The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab Dispos 31:731–41.
   PubMed Web of Science ®Google Scholar
• Sandherr M, Maschmeyer G. (2011). Pharmacology and metabolism of voriconazole and posaconazole in the treatment of invasive aspergillosis: review of the literature . Eur J Med Res 16:139–44.
   PubMed Web of Science ®Google Scholar
• Sasai M, Saeki Y, Ohshima S, et al. (1999). Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice. Arthritis Rheum 42:1635–43.
   PubMed Web of Science ®Google Scholar
• Scott LJ, Simpson D. (2007). Voriconazole: a review of its use in the management of invasive fungal infections. Drugs 67:269–98.
   PubMed Web of Science ®Google Scholar
• Shen X, Yao Z, Johnson T, et al. (2008). A portal vein cannulation technique for drug discovery in mice. Lab Anim (NY) 37:41–4.
   PubMed Web of Science ®Google Scholar
• Sili U, Bilgin H, Masania R, et al. (2015). Successful treatment of an invasive fungal infection caused by Talaromyces sp. with voriconazole. Med Mycol Case Rep 8:21–3.
   PubMed Web of Science ®Google Scholar
• Srinivas NR. (2010). Altered disposition of drugs in acute renal failure rat models: drug development strategies and perspectives. Arzneimittelforschung 60:731–48.
   PubMed Web of Science ®Google Scholar
• Tragiannidis A, Kyriakidis I, Zündorf I, Groll AH. (2017). Invasive fungal infections in pediatric patients treated with tumor necrosis alpha (TNF-α) inhibitors. Mycoses 60:222–9.
   PubMed Web of Science ®Google Scholar
• Xu SX, Shen JL, Tang XF, et al. (2016). Newer antifungal agents micafungin and voriconazole for fungal infection prevention during hematopoietic cell transplantation: a meta-analysis. Eur Rev Med Pharmacol Sci 20:381–90.
   PubMed Web of Science ®Google Scholar
• Young B, Tambyah PA. (2012). Infectious disease trends among immunocompromised hosts. Singapore Med J 53:223–30.
   PubMed Web of Science ®Google Scholar